The prognosis and therapeutic management of patients hospitalized for heart failure in 2010-2020
- PMID: 35444330
- DOI: 10.5507/bp.2022.020
The prognosis and therapeutic management of patients hospitalized for heart failure in 2010-2020
Abstract
Aims: We analyzed the mortality risk and its predictors in patients hospitalized for heart failure (HF).
Methods: Patients discharged from hospitalization for acute decompensation of HF in 2010-2020 and younger than 86 years were followed (n=4097). We assessed the incidence and trends of all-cause death, its main predictors, and the pharmacotherapy recommended at discharge from the hospital.
Results: The 30 days all-cause mortality was in discharged patients 3.2%, while 1-year 20.4% and 5-years 55.4%. We observed a modest trend to decreased 1-year mortality risk over time. Any increase of year of hospitalization by one was associated with about 5% lower risk in the fully adjusted model. Regarding predictors of 1-year mortality risk, a positive association was found for age over 65, history of malignancy, and peak brain natriuretic peptide during hospitalization ≥10times higher than normal concentration. In contrast, as protective factors, we identified LDL ≥1.8 mmol/L, treatment with beta-blockers, renin-angiotensin axis blockers, statins, and implanted cardioverter in the same regression model. The ejection fraction category and primary etiology of HF (coronary artery disease vs. others) did not significantly affect the mortality risk in a fully adjusted model.
Conclusions: Despite advances in cardiovascular disease management over the last two decades, the prognosis of patients hospitalized for heart failure remained highly unfavorable.
Keywords: cardiac decompensation; hospitalization; mortality risk; pharmacotherapy.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Similar articles
-
Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.ESC Heart Fail. 2019 Jun;6(3):475-486. doi: 10.1002/ehf2.12418. Epub 2019 Mar 3. ESC Heart Fail. 2019. PMID: 30829002 Free PMC article.
-
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.JAMA Cardiol. 2018 Dec 1;3(12):1226-1231. doi: 10.1001/jamacardio.2018.3957. JAMA Cardiol. 2018. PMID: 30484837 Free PMC article. Clinical Trial.
-
Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.Int J Cardiol. 2017 Apr 1;232:86-92. doi: 10.1016/j.ijcard.2017.01.048. Epub 2017 Jan 5. Int J Cardiol. 2017. PMID: 28100428
-
Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials.Heart Lung Circ. 2014 Oct;23(10):970-7. doi: 10.1016/j.hlc.2014.05.005. Epub 2014 May 28. Heart Lung Circ. 2014. PMID: 24954758 Review.
-
No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials.PLoS One. 2017 Feb 6;12(2):e0171168. doi: 10.1371/journal.pone.0171168. eCollection 2017. PLoS One. 2017. PMID: 28166237 Free PMC article.
Cited by
-
Prognostic value of lipid parameters among patients with heart failure: A systematic review and meta-analysis.ESC Heart Fail. 2025 Aug;12(4):2691-2701. doi: 10.1002/ehf2.15315. Epub 2025 May 24. ESC Heart Fail. 2025. PMID: 40411472 Free PMC article.
-
The long-term impact of increased red blood cell distribution width detected during hospitalization for heart failure.Biomark Med. 2024;18(19):831-842. doi: 10.1080/17520363.2024.2395237. Epub 2024 Sep 10. Biomark Med. 2024. PMID: 39254358
References
-
- Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Michael Felker G, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021;23(3):352-80. - PubMed - DOI
-
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599-726. - PubMed - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous